BRPI0515935B8 - pirimidinas heterociclil- ou 5-carbo substituídas para inibição de hiv, e composição farmacêutica - Google Patents
pirimidinas heterociclil- ou 5-carbo substituídas para inibição de hiv, e composição farmacêuticaInfo
- Publication number
- BRPI0515935B8 BRPI0515935B8 BRPI0515935A BRPI0515935A BRPI0515935B8 BR PI0515935 B8 BRPI0515935 B8 BR PI0515935B8 BR PI0515935 A BRPI0515935 A BR PI0515935A BR PI0515935 A BRPI0515935 A BR PI0515935A BR PI0515935 B8 BRPI0515935 B8 BR PI0515935B8
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- optionally substituted
- substituted
- amino
- alkyloxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04104814 | 2004-09-30 | ||
PCT/EP2005/054931 WO2006035068A2 (en) | 2004-09-30 | 2005-09-29 | Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0515935A BRPI0515935A (pt) | 2008-08-12 |
BRPI0515935B1 BRPI0515935B1 (pt) | 2019-11-19 |
BRPI0515935B8 true BRPI0515935B8 (pt) | 2021-05-25 |
Family
ID=34929640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0515935A BRPI0515935B8 (pt) | 2004-09-30 | 2005-09-29 | pirimidinas heterociclil- ou 5-carbo substituídas para inibição de hiv, e composição farmacêutica |
Country Status (17)
Country | Link |
---|---|
US (1) | US7531548B2 (pt) |
EP (1) | EP1797048B1 (pt) |
JP (1) | JP5162245B2 (pt) |
KR (1) | KR20070057798A (pt) |
CN (1) | CN101031550B (pt) |
AR (1) | AR050970A1 (pt) |
AT (1) | ATE520672T1 (pt) |
AU (1) | AU2005288865B2 (pt) |
BR (1) | BRPI0515935B8 (pt) |
CA (1) | CA2573976C (pt) |
ES (1) | ES2371924T3 (pt) |
IL (1) | IL180760A (pt) |
MX (1) | MX2007003798A (pt) |
RU (1) | RU2403244C2 (pt) |
TW (1) | TW200626560A (pt) |
WO (1) | WO2006035068A2 (pt) |
ZA (1) | ZA200702655B (pt) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1656372E (pt) | 2003-07-30 | 2013-06-27 | Rigel Pharmaceuticals Inc | Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina |
AU2005288864B2 (en) * | 2004-09-30 | 2012-08-23 | Janssen Sciences Ireland Uc | HIV inhibiting 5-heterocyclyl pyrimidines |
WO2006035069A1 (en) * | 2004-09-30 | 2006-04-06 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 5-substituted pyrimidines |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
NZ563454A (en) | 2005-06-08 | 2011-03-31 | Rigel Pharmaceuticals Inc | 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway |
DE602007009508D1 (de) * | 2006-03-30 | 2010-11-11 | Little Island Co Cork | Hiv-inhibierende 5-(hydroxymethylen- und aminomethylen) substituierte pyrimidine |
US8933089B2 (en) | 2006-03-30 | 2015-01-13 | Janssen R & D Ireland | HIV inhibiting 5-amido substituted pyrimidines |
JP5415957B2 (ja) | 2006-12-13 | 2014-02-12 | エフ.ホフマン−ラ ロシュ アーゲー | 非ヌクレオシド逆転写酵素阻害剤としての2−(ピペリジン−4−イル)−4−フェノキシ−又はフェニルアミノ−ピリミジン誘導体 |
CN101573343B (zh) * | 2006-12-29 | 2016-02-24 | 爱尔兰詹森科学公司 | 抑制人免疫缺陷病毒的6-取代的嘧啶 |
AU2007341228B2 (en) * | 2006-12-29 | 2013-04-18 | Janssen Sciences Ireland Uc | HIV inhibiting 5,6-substituted pyrimidines |
WO2008118823A2 (en) * | 2007-03-26 | 2008-10-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
DK2361248T3 (en) | 2008-06-27 | 2019-01-14 | Celgene Car Llc | Heteroberl compounds and uses thereof |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
AR074210A1 (es) | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina como inhibidores de ptk2-quinasa |
TW201024281A (en) | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
ES2659725T3 (es) | 2009-05-05 | 2018-03-19 | Dana-Farber Cancer Institute, Inc. | Inhibidores de EGFR y procedimiento de tratamiento de trastornos |
AP2858A (en) * | 2009-06-22 | 2014-02-28 | Emcure Pharmaceuticals Ltd | Process for synthesis of a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor |
EP3144298A1 (en) | 2010-08-10 | 2017-03-22 | Celgene Avilomics Research, Inc. | Besylate salt of a btk inhibitor |
JP5956999B2 (ja) | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | ヘテロアリール化合物およびその使用 |
MX2013004894A (es) | 2010-11-01 | 2013-10-17 | Celgene Avilomics Res Inc | Compuestos heterociclicos y usos de los mismos. |
US8796255B2 (en) | 2010-11-10 | 2014-08-05 | Celgene Avilomics Research, Inc | Mutant-selective EGFR inhibitors and uses thereof |
AR088570A1 (es) | 2011-10-28 | 2014-06-18 | Celgene Avilomics Res Inc | Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton |
JP6317319B2 (ja) | 2012-03-15 | 2018-04-25 | セルジーン シーエーアール エルエルシー | 上皮成長因子受容体キナーゼ阻害剤の固体形態 |
MX356179B (es) | 2012-03-15 | 2018-05-17 | Celgene Avilomics Res Inc | Sales de un inhibidor de cinasa del receptor del factor de crecimiento epidermico. |
EP2935226A4 (en) | 2012-12-21 | 2016-11-02 | Celgene Avilomics Res Inc | HETEROARYL COMPOUNDS AND USES THEREOF |
CN105188371A (zh) | 2013-02-08 | 2015-12-23 | 西建阿维拉米斯研究公司 | Erk抑制剂及其用途 |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
ES2741785T3 (es) | 2014-08-13 | 2020-02-12 | Celgene Car Llc | Formas y composiciones de un inhibidor de ERK |
WO2021167495A1 (en) | 2020-02-19 | 2021-08-26 | Pharmasyntez, Joint Stock Company | Pyrimidine-based bicycles as antiviral agents for the treatment and prevention of hiv infection |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
KR20230155351A (ko) * | 2022-05-03 | 2023-11-10 | 한국화학연구원 | 5-클로로-2,4-다이아미노피리미딘을 포함하는 키나아제 억제 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9012592D0 (en) * | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
NO311614B1 (no) | 1996-10-01 | 2001-12-17 | Janssen Pharmaceutica Nv | Substituerte diamino-1,3,5-triazinderivater |
EP0945443B9 (en) * | 1998-03-27 | 2003-08-13 | Janssen Pharmaceutica N.V. | HIV inhibiting pyrimidine derivatives |
DE69943247D1 (de) * | 1998-03-27 | 2011-04-14 | Janssen Pharmaceutica Nv | HIV hemmende Pyrimidin Derivate |
EP0945447A1 (en) | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections |
PL204427B1 (pl) | 1998-11-10 | 2010-01-29 | Janssen Pharmaceutica Nv | Hamująca replikację wirusa HIV pochodna pirymidyny, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna |
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
WO2001085700A2 (en) | 2000-05-08 | 2001-11-15 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines and triazines |
ES2265450T3 (es) * | 2000-12-21 | 2007-02-16 | Vertex Pharmaceuticals Incorporated | Compuestos de pirazol utiles como inhibidores de la proteina quinasa. |
JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
NZ539823A (en) * | 2002-11-28 | 2008-04-30 | Schering Aktiengessellschaft | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
-
2005
- 2005-09-29 ES ES05803358T patent/ES2371924T3/es active Active
- 2005-09-29 MX MX2007003798A patent/MX2007003798A/es active IP Right Grant
- 2005-09-29 US US11/576,068 patent/US7531548B2/en active Active
- 2005-09-29 KR KR1020077003634A patent/KR20070057798A/ko not_active Application Discontinuation
- 2005-09-29 TW TW094134106A patent/TW200626560A/zh unknown
- 2005-09-29 AT AT05803358T patent/ATE520672T1/de not_active IP Right Cessation
- 2005-09-29 RU RU2007116161/04A patent/RU2403244C2/ru active
- 2005-09-29 BR BRPI0515935A patent/BRPI0515935B8/pt not_active IP Right Cessation
- 2005-09-29 CN CN200580033118.3A patent/CN101031550B/zh not_active Expired - Fee Related
- 2005-09-29 CA CA2573976A patent/CA2573976C/en not_active Expired - Fee Related
- 2005-09-29 EP EP05803358A patent/EP1797048B1/en active Active
- 2005-09-29 WO PCT/EP2005/054931 patent/WO2006035068A2/en active Application Filing
- 2005-09-29 JP JP2007534027A patent/JP5162245B2/ja not_active Expired - Fee Related
- 2005-09-29 AU AU2005288865A patent/AU2005288865B2/en not_active Ceased
- 2005-09-30 AR ARP050104154A patent/AR050970A1/es not_active Application Discontinuation
-
2007
- 2007-01-17 IL IL180760A patent/IL180760A/en active IP Right Grant
- 2007-03-29 ZA ZA200702655A patent/ZA200702655B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN101031550B (zh) | 2015-05-27 |
AU2005288865A1 (en) | 2006-04-06 |
TW200626560A (en) | 2006-08-01 |
US7531548B2 (en) | 2009-05-12 |
ES2371924T3 (es) | 2012-01-11 |
IL180760A0 (en) | 2007-06-03 |
WO2006035068A3 (en) | 2006-08-31 |
EP1797048B1 (en) | 2011-08-17 |
AR050970A1 (es) | 2006-12-06 |
ATE520672T1 (de) | 2011-09-15 |
JP5162245B2 (ja) | 2013-03-13 |
IL180760A (en) | 2013-02-28 |
MX2007003798A (es) | 2007-04-23 |
US20070208022A1 (en) | 2007-09-06 |
WO2006035068A2 (en) | 2006-04-06 |
CN101031550A (zh) | 2007-09-05 |
CA2573976C (en) | 2014-04-29 |
CA2573976A1 (en) | 2006-04-06 |
EP1797048A2 (en) | 2007-06-20 |
AU2005288865B2 (en) | 2012-07-19 |
KR20070057798A (ko) | 2007-06-07 |
BRPI0515935A (pt) | 2008-08-12 |
BRPI0515935B1 (pt) | 2019-11-19 |
JP2008514680A (ja) | 2008-05-08 |
RU2007116161A (ru) | 2008-11-10 |
ZA200702655B (en) | 2008-09-25 |
RU2403244C2 (ru) | 2010-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0515935B8 (pt) | pirimidinas heterociclil- ou 5-carbo substituídas para inibição de hiv, e composição farmacêutica | |
MX2007005159A (es) | Derivados de pirimidina biciclicos inhibidores del vih. | |
TW200626574A (en) | HIV inhibiting 5-heterocyclyl pyrimidines | |
MX2010001677A (es) | Derivados de 4-(9-(3,3-difluorociclopentil)-5,7,7-trimetil-6-oxo-6 ,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-ilamino)-3-me toxibenzamida como inhibidores de las proteinas cinasas humanas plk1 a plk4 para el tratamiento de enfermedades proli | |
BRPI0407741A (pt) | pirimidinas e triazinas de inibição de replicação de hiv | |
BR122015023612B8 (pt) | compostos derivados de pirimidina, seu uso, composição farmacêutica e produto | |
TNSN06411A1 (en) | Pyrimidine urea derivatives as kinase inhibitors | |
NO20063231L (no) | Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer | |
BR0213522B1 (pt) | compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto | |
BR0317749A (pt) | Composto, composição farmacêutica, e, uso de um composto | |
HRP20120351T1 (hr) | Macrociklički derivati kinazolina kao antiproliferativna sredstva | |
NZ604345A (en) | Pyrazolo[1,5-a]pyrimidines as antiviral agents | |
HUP0201789A2 (hu) | A légzőrendszerre ható szinciciális vírus replikációját gátló vegyületek | |
RU2015148189A (ru) | ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1 | |
MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
WO2007146230A3 (en) | Non-nucleoside reverse transcriptase inhibitors | |
TW200626561A (en) | HIV inhibiting 5-substituted pyrimidines | |
MX2007006635A (es) | Formulacion farmaceutica de inhibidores dela carboxamida vih integrasa que contienen una composicion que controla la velocidad de liberacion. | |
WO2005120516A3 (en) | Hiv integrase inhibitors | |
ECSP099767A (es) | Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas | |
BR0211171A (pt) | Compostos quìmicos | |
MY138996A (en) | 4-amino-5-cyanopyrimidine derivatives | |
SI1971329T1 (en) | Triazine derivatives for use in the treatment of cicatrization | |
EA200500802A1 (ru) | Лечение латентного туберкулёза | |
TW200733981A (en) | Hair fitness/body improving agents and hair cosmetics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: TIBOTEC PHARMACEUTICALS (IE) |
|
B25D | Requested change of name of applicant approved |
Owner name: JANSSEN R AND D IRELAND (IE) |
|
B25A | Requested transfer of rights approved |
Owner name: JANSSEN SCIENCES IRELAND UC (IE) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/11/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/09/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2690 DE 26-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |